Artiva Biotherapeutics ARTV
NASDAQ ARTV
$4.07 +0.01 (+0.25%)
At close: Nov 11, 2026 · 4:00 PM EST

Artiva Biotherapeutics (ARTV) EBITDA Margin (2023 - 2024)

Updated

Artiva Biotherapeutics' EBITDA Margin came in at -25837.05% for FY2024, down 25752.24 percentage points from -84.81% in FY2023.

Analysis

Artiva Biotherapeutics (ARTV) EBITDA Margin (2023 - 2024) Analysis & Trends

  • Per Business Quant, earlier years put EBITDA Margin at -84.81% in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Artiva Biotherapeutics 200.70 Mn -118.40 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -5,539.84%
Dec 31, 2023 -484.09%
Sep 30, 2023 42.64%
Jun 30, 2023 -323.82%
API Access

Artiva Biotherapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ARTV&period=max&api_key=YOUR_API_KEY